GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2010

Ingenuity Systems and Sage Couple Respective Software and Predictive Models

  • Ingenuity Systems has given Sage Bionetworks the right to utilize its analysis software, IPA®, and the Ingenuity Knowledge Base of structured biomedical findings to inform and enhance Sage's predictive disease models.

    Sage's web portal will also provide links to the Ingenuity Knowledge Base and IPA. The company's content, algorithms, and predictive disease networks will also be made available within Ingenuity products like IPA.

    Researchers will thus be able to use the content and algorithms from Sage within IPA to analyze molecular data, generate testable hypotheses, and build and visualize predictive disease models. "Leveraging their high-quality, expert-reviewed Ingenuity Knowledge Base Findings and their powerful pathway analytics in our research will enhance and add functionality to our predictive disease networks and algorithms," says Stephen Friend, president, Sage Bionetworks.

    The IPA software helps researchers model, analyze, and understand the complex biological and chemical systems at the core of life science research. It integrates data from a variety of experimental platforms and provides insight into the molecular and chemical interactions, cellular phenotypes, and disease processes of a system.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?